⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
India has over 268 million tobacco users — one of the largest in the world. Tobacco use in India takes many forms beyond cigarettes: bidis (hand-rolled tobacco in tendu leaves), pan masala, gutka, khaini, hookah, and smokeless chewing tobacco. For GLP-1 medication users who also smoke or use tobacco, the interaction of these two factors carries significant health implications that most doctors have limited time to discuss in a standard consultation.
This guide is written for Indian GLP-1 users who are current tobacco users, those considering quitting, and those who have already quit and worry about weight gain. Consult your healthcare provider before starting any medication and always discuss tobacco use openly with your doctor — it directly affects your cardiovascular risk assessment.
GLP-1 medications are primarily prescribed for two conditions: Type 2 diabetes and obesity. Both conditions independently elevate cardiovascular risk. Tobacco use independently elevates cardiovascular risk. Together, the three form a cardiovascular risk triangle that dramatically increases the likelihood of heart attack, stroke, peripheral vascular disease, and kidney disease.
WHO data from India shows that individuals with diabetes who also smoke have:
The good news: this triangle is not permanent. The GLP-1 medications Ozempic and Wegovy have now been shown in the SELECT trial (2023) to reduce major cardiovascular events by 20% in overweight/obese people without diabetes. For users with diabetes and obesity, the cardiovascular benefit is even more significant. Stopping tobacco simultaneously with starting GLP-1 therapy produces synergistic cardiovascular risk reduction.
The relationship between nicotine and weight is complex and frequently misunderstood:
Nicotine suppresses appetite — via nicotinic acetylcholine receptors in the hypothalamus. This is why many smokers are thinner than their non-smoking peers and why quitting smoking often causes weight gain (the appetite-suppressing effect of nicotine is removed).
Average weight gain after quitting smoking: 4–5 kg in the first year, concentrated in the first 3 months. For some individuals, it can be 8–10 kg. This weight gain discourages many Indian smokers from quitting, particularly those already concerned about their weight.
This is precisely where GLP-1 medications can help. For a smoker starting GLP-1 therapy, the medication provides appetite suppression to offset the weight gain that typically accompanies smoking cessation. Multiple case series and clinical discussions in endocrinology literature describe GLP-1 medications as the ideal pharmacological support for simultaneous smoking cessation, because they address the appetite rebound mechanism directly.
GLP-1 receptors are not only in the gut and pancreas — they are present in the brain's mesolimbic dopamine system (the reward circuit), which governs addictive behaviour toward food, alcohol, nicotine, and other substances.
Research is now showing that GLP-1 receptor activation reduces reward salience of addictive substances — making them feel less compelling. This is the same mechanism proposed for the food noise reduction many GLP-1 users describe.
For nicotine specifically:
This means that some GLP-1 users in India may find — often to their surprise — that their desire to smoke reduces without specific anti-smoking interventions. This effect is not universal, and the evidence base is still building, but it is a clinically recognised phenomenon.
Cigarettes: Standard filter cigarettes carry the well-characterised cardiovascular, lung, and cancer risks of tobacco smoking. No specific chemical interaction between cigarette smoke components and semaglutide or tirzepatide is known.
Bidis: Bidis (hand-rolled tobacco in tendu leaf) are more commonly smoked in India than cigarettes, particularly in rural areas and among daily wage workers. Bidis produce higher concentrations of tar, carbon monoxide, and nicotine per smoke than cigarettes due to unfiltered inhalation. The cardiovascular risk from bidi smoking is equivalent to or greater than cigarette smoking.
Gutka and pan masala: These are smokeless tobacco products containing tobacco, areca nut (supari), slaked lime, and flavourings. They are associated with a dramatically elevated risk of oral submucous fibrosis, oral cancer, and oesophageal cancer. They are particularly common in India and are frequently not considered "serious" tobacco use by users themselves.
Key point for GLP-1 users who use gutka or pan masala: There is no known direct chemical interaction with GLP-1 medications, but the oral cancer risk means any oral lesion, difficulty swallowing, or change in mouth sensation should be reported to a doctor immediately — these can worsen insidiously and are often dismissed as mouth ulcers. GLP-1-related nausea can sometimes mask early oral cancer symptoms.
Hookah: Single hookah sessions can deliver nicotine and toxins equivalent to smoking 40–50 cigarettes. Social hookah use is increasingly common among urban Indian youth — including those who would not identify as "smokers." The cardiovascular and lung risks apply equally.
This is actually an excellent moment to consider cessation. Your doctor has likely already discussed your cardiovascular risk; tobacco compounds it dramatically. Options:
Post-cessation weight gain is real but GLP-1 medications can prevent or reverse it. If you quit smoking 6–24 months ago and notice weight gain, GLP-1 therapy may be specifically effective for you because it targets the exact mechanism (appetite dysregulation from nicotine withdrawal) that drives post-cessation weight gain.
Quitting smokeless tobacco does not typically cause significant weight gain (unlike cigarettes), because the nicotine delivery is less acute and the appetite-suppression mechanism is weaker. The primary reason to quit is cancer prevention, and GLP-1 medications do not directly help with this. Seek support from a tobacco cessation clinic — AIIMS, NIMHANS, Tata Memorial, and most district cancer hospitals in India have cessation counselling services (quitline: 1800-11-2356, toll-free).
1. Not telling your doctor you smoke. Tobacco use affects cardiovascular risk stratification, medication selection, blood pressure targets, and monitoring frequency. Always disclose it. There is no judgement — it is medical information.
2. Believing bidis are "natural" and therefore safer. Bidis are tobacco products with well-documented health risks. The tendu leaf does not neutralise tobacco toxins.
3. Stopping smoking suddenly without a plan on GLP-1 initiation day. Sudden cessation alongside a new medication that is already causing nausea and fatigue can be overwhelming. Plan the quit date for week 3–4 of GLP-1 therapy, when tolerability has improved.
4. Using e-cigarettes as a "safer" bridge while on GLP-1. The safety of combining e-cigarettes (vaping) with GLP-1 medications specifically has not been studied. E-cigarettes deliver nicotine and other compounds. Do not use them as a harm-reduction substitute without medical guidance.
If you are a current or recent tobacco user starting GLP-1 therapy, discuss the following monitoring schedule with your doctor:
Q: I smoke 2 cigarettes a day — is that too few to matter? No. Even 1–5 cigarettes per day is associated with significantly elevated cardiovascular risk. The relationship between smoking dose and cardiovascular risk is not linear at low doses — meaning the harm from 2 cigarettes is disproportionately high.
Q: My father says bidis are traditional and harmless. Should I be concerned? Bidi smoking has been extensively studied in India. ICMR and WHO data confirm that bidi smokers have comparable or higher lung cancer, COPD, and cardiovascular mortality rates as cigarette smokers. The traditional perception of bidis as natural or safe is not supported by clinical evidence.
Q: Can GLP-1 medications replace nicotine replacement therapy for quitting? Not yet officially. GLP-1 medications are not approved in India or internationally as smoking cessation medications. The evidence for their anti-craving effects is promising but not yet sufficient for prescribing guidelines. Use evidence-based cessation support (NRT, counselling, quitline) alongside GLP-1 therapy.
Q: Will quitting smoking affect how my GLP-1 medication works? Cessation improves insulin sensitivity (nicotine worsens insulin resistance), which means blood sugar control typically improves after quitting. This is a benefit, not a problem. If you take insulin or sulphonylureas alongside GLP-1, monitor for hypoglycaemia more closely in the first few weeks after quitting.
Tobacco use compounds the cardiovascular risk that GLP-1 therapy is partly designed to reduce. The medications Ozempic, Wegovy, and Mounjaro offer not just weight loss and blood sugar benefits — they may also reduce nicotine cravings as a secondary mechanism. For Indian users who smoke or chew tobacco, starting GLP-1 therapy is an ideal moment to plan smoking cessation, with the medication's appetite suppression serving as a built-in buffer against post-cessation weight gain.
Consult your healthcare provider before starting any medication, disclose your tobacco use clearly, and explore cessation support proactively — quitting smoking alongside GLP-1 therapy may be one of the most powerful health decisions you can make.
